Improving Transfusion Independence With JAK Inhibitor Therapy

John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

TOTAL CME

Transfusion Independence and Duration of TI With Momelotinib





BAT, best available therapy; BID, twice daily; MMB, momelotinib; RUX, ruxolitinib; TI, transfusion independence.

Verstovsek S, et al. *Blood*. 2020;136(Supplement 1):51-52.

Robust Survival for Prior JAKi-Treated Patients With Momelotinib



BAT, best available therapy; JAKi, Janus-associated kinase inhibitor; MMB, momelotinib; OS, overall survival; RUX, ruxolitinib.

Verstovsek S, et al. *Blood*. 2020;136(Supplement 1):51-52.

Week 24 TI Responses[a] Were Sustained Through Week 48 With Momelotinib





- Week 24 TI response was **31% in the MMB group and 20% in the DAN group**
  - Consecutive 12-week TI-R[b] was 44.6% in the MMB group and 29.2% in the DAN group (Poster #3028)
- Week 24 TI response was maintained in 36 of 40 (90%) MMB→MMB and 10 of 13 (77%) DAN→MMB patients

[a] Defined as not requiring RBC transfusion in the prior 12 weeks and Hgb levels ≥8 g/dL. [b] Consecutive 12-week TI-R (defined as absence of RBC transfusions and no Hgb measurement below 8 g/dL over any 12-week period through week 24).
BL, baseline; DAN, danazol; Hgb, hemoglobin; ITT, intention-to-treat; MMB, momelotinib; OL, open-label; RBC, red blood cell; RT, randomized treatment; TI, transfusion independence; TI-R, TI response.
Gerds AT, et. *Blood*. 2022;140(Supplement 1):1514-1517. Gerds AT, et al. *Lancet Haematol*. 2023;10(9):e735-e746.

More Patients on Pacritinib Achieved Transfusion Independence[1] (Gale Criteria[2])

TI Conversion Rate

Pacritinib N = 41	BAT N = 43	*P* Value
37%	7%	.001

- TI conversion better on pacritinib than BAT, including patients receiving erythroid support agents as BAT
- Erythroid support agents were prohibited on the pacritinib arm

Gale criteria: no RBC transfusions over a 12-week period



AB, allele burden; BAT, best available therapy; BID, twice daily; CI, confidence interval; ES, erythroid support; JAK, Janus-associated kinase; PAC, pacritinib; PLT, platelets; RBC, red blood cell; RUX, ruxolitinib; RUX naïve (no RUX prior to first dose); TI, transfusion independence.

1. Oh S, et al. *Blood Adv*. 2023;7:5835-5842. 2. Gale RP, et al. *Leuk Res*. 2011;35(1):8-11.

More Patients on Pacritinib Achieved Transfusion Independence[1] (SIMPLIFY)

TI Conversion Rate

Pacritinib N = 41	BAT N = 43	*P* Value
24%	5%	0.013

Similar results based on SIMPLIFY criteria for TI[2,3]

- No RBC transfusion and no hemoglobin < 8g/dL in the prior 12-weeks



AB, allele burden; BAT, best available therapy; BID, twice daily; CI, confidence interval; ES, erythroid support; JAK, Janus-associated kinase; PAC, pacritinib; PLT, platelets; RBC, red blood cell; RUX, ruxolitinib; RUX naïve (no RUX prior to first dose); TI, transfusion independence.

Oh S, et al. *Blood Adv.* 2023;7:5835-5842. 2. Mesa RA, et al. *J Clin Oncol*. 2017;35(34):3844-3850. 3. Harrison CN, et al. *Lancet Haematol.* 2018;5(2):e73-e81.

More Patients on Pacritinib Had ≥50% Transfusion Reduction

Transfusion Reduction

Pacritinib N = 41	BAT N = 43	*P* Value
49%	9%	.0001

- Clinically significant reduction in transfusion burden more common on pacritinib



AB, allele burden; BAT, best available therapy; BID, twice daily; CI, confidence interval; ES, erythroid support; JAK, Janus-associated kinase; PAC, pacritinib; PLT, platelets; RUX, ruxolitinib; RUX naïve (no RUX prior to first dose).

Oh S, et al. *Blood Adv.* 2023;7:5835-5842.

Summary

- Durable anemia responses demonstrated with:
  - Momelotinib in the SIMPLIFY and MOMENTUM studies
  - Pacritinib in the PERSIST-2 study, including in patients with low platelet counts
- Both pacritinib and momelotinib provide reduced spleen and symptom burden and improve disease-related anemia